WO2004113275A3 - Methodes et compositions pour traiter les maladies liees a l'amyloide - Google Patents

Methodes et compositions pour traiter les maladies liees a l'amyloide Download PDF

Info

Publication number
WO2004113275A3
WO2004113275A3 PCT/IB2004/002375 IB2004002375W WO2004113275A3 WO 2004113275 A3 WO2004113275 A3 WO 2004113275A3 IB 2004002375 W IB2004002375 W IB 2004002375W WO 2004113275 A3 WO2004113275 A3 WO 2004113275A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
related diseases
treating amyloid
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/002375
Other languages
English (en)
Other versions
WO2004113275A2 (fr
Inventor
Xianqi Kong
David Migneault
Isabelle Valade
Xinfu Wu
Francine Gervais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health International Ltd
Original Assignee
Neurochem International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/871,365 external-priority patent/US7244764B2/en
Priority claimed from US10/871,514 external-priority patent/US7414076B2/en
Priority to AU2004249529A priority Critical patent/AU2004249529A1/en
Priority to NZ544684A priority patent/NZ544684A/en
Priority to CN2004800242077A priority patent/CN1839118B/zh
Priority to UAA200600637A priority patent/UA96115C2/uk
Priority to CA2529257A priority patent/CA2529257C/fr
Priority to KR1020057024647A priority patent/KR101124935B1/ko
Priority to EP04744034A priority patent/EP1644325A2/fr
Priority to EA200600078A priority patent/EA012429B1/ru
Application filed by Neurochem International Ltd filed Critical Neurochem International Ltd
Priority to JP2006516599A priority patent/JP5146714B2/ja
Priority to MXPA05014166A priority patent/MXPA05014166A/es
Priority to BRPI0411743-3A priority patent/BRPI0411743A/pt
Publication of WO2004113275A2 publication Critical patent/WO2004113275A2/fr
Publication of WO2004113275A3 publication Critical patent/WO2004113275A3/fr
Priority to IL172194A priority patent/IL172194A/en
Priority to NO20055894A priority patent/NO335084B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/69—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a carbon skeleton substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/02—Thiosulfates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des méthodes, des composés, des compositions pharmaceutiques et des trousses pour traiter ou prévenir les maladies liées à l'amyloïde.
PCT/IB2004/002375 2003-06-23 2004-06-21 Methodes et compositions pour traiter les maladies liees a l'amyloide Ceased WO2004113275A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MXPA05014166A MXPA05014166A (es) 2003-06-23 2004-06-21 Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
BRPI0411743-3A BRPI0411743A (pt) 2003-06-23 2004-06-21 método e composições para tratar doenças relacionadas a amilóides
JP2006516599A JP5146714B2 (ja) 2003-06-23 2004-06-21 アミロイド関連疾患を治療するための方法および組成物
CN2004800242077A CN1839118B (zh) 2003-06-23 2004-06-21 治疗淀粉样相关疾病用的方法与组合物
UAA200600637A UA96115C2 (uk) 2003-06-23 2004-06-21 Спосіб і композиція для лікування амілоїдогенних захворювань
CA2529257A CA2529257C (fr) 2003-06-23 2004-06-21 Methodes et compositions pour traiter les maladies liees a l'amyloide
KR1020057024647A KR101124935B1 (ko) 2003-06-23 2004-06-21 아밀로이드 관련 질환의 치료 방법 및 조성물
EP04744034A EP1644325A2 (fr) 2003-06-23 2004-06-21 Methodes et compositions pour traiter les maladies liees a l'amyloide
EA200600078A EA012429B1 (ru) 2003-06-23 2004-06-21 Способы и композиции для лечения амилоидных заболеваний
AU2004249529A AU2004249529A1 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
NZ544684A NZ544684A (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
IL172194A IL172194A (en) 2003-06-23 2005-11-24 A compound and pharmaceutical composition containing it for the treatment or prevention of amyloid-dependent diseases
NO20055894A NO335084B1 (no) 2003-06-23 2005-12-12 Forbindelser og preparater og deres anvendelse for behandling av amyloidrelaterte sykdommer

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US48090603P 2003-06-23 2003-06-23
US60/480,906 2003-06-23
US51204703P 2003-10-17 2003-10-17
US60/512,047 2003-10-17
US10/871,365 2004-06-18
US10/871,365 US7244764B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,514 2004-06-18
US10/871,514 US7414076B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases

Publications (2)

Publication Number Publication Date
WO2004113275A2 WO2004113275A2 (fr) 2004-12-29
WO2004113275A3 true WO2004113275A3 (fr) 2005-10-27

Family

ID=33545555

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2004/002337 Ceased WO2004113277A2 (fr) 2003-06-23 2004-06-21 Procedes et compositions de traitement de maladies associees aux amyloides
PCT/IB2004/002375 Ceased WO2004113275A2 (fr) 2003-06-23 2004-06-21 Methodes et compositions pour traiter les maladies liees a l'amyloide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002337 Ceased WO2004113277A2 (fr) 2003-06-23 2004-06-21 Procedes et compositions de traitement de maladies associees aux amyloides

Country Status (12)

Country Link
EP (2) EP1658264A2 (fr)
JP (2) JP2007516938A (fr)
KR (1) KR101124935B1 (fr)
AU (2) AU2004249527A1 (fr)
BR (1) BRPI0411743A (fr)
CA (2) CA2529256A1 (fr)
EA (1) EA012429B1 (fr)
MX (2) MXPA05013977A (fr)
NO (1) NO335084B1 (fr)
NZ (1) NZ544684A (fr)
UA (1) UA96115C2 (fr)
WO (2) WO2004113277A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580859B2 (en) 2008-08-01 2013-11-12 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2660607B2 (ja) 1990-09-14 1997-10-08 株式会社エース電研 金属検知装置およびパチンコゲーム機
JP2700212B2 (ja) 1990-09-14 1998-01-19 株式会社エース電研 金属センサおよびパチンコゲーム機
JP2660608B2 (ja) 1990-10-04 1997-10-08 株式会社エース電研 金属検知装置およびパチンコゲーム機
JP2700215B2 (ja) 1990-11-24 1998-01-19 株式会社エース電研 パチンコゲーム機
JP2700213B2 (ja) 1990-11-24 1998-01-19 株式会社エース電研 パチンコ玉検知装置およびパチンコゲーム機
JP2700214B2 (ja) 1990-11-24 1998-01-19 株式会社エース電研 パチンコゲーム機
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1658264A2 (fr) * 2003-06-23 2006-05-24 Neurochem (International) Limited Procedes et compositions de traitement de maladies associees aux amyloides
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CA2586334A1 (fr) * 2004-11-16 2006-06-08 Neurochem (International) Limited Composes pour le traitement de maladies associees au snc et a la proteine amyloide
WO2006085149A2 (fr) * 2004-12-22 2006-08-17 Neurochem (International) Limited Methodes et compositions de traitement de maladies liees a l'amyloide
CA2624693A1 (fr) * 2005-09-30 2007-06-07 Neurochem (International) Limited Methodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques
BRPI0722382A2 (pt) * 2006-04-14 2012-06-05 Prana Biotechnology Ltd compostos úteis para o tratamento de cáncer
KR100883132B1 (ko) 2006-10-24 2009-02-10 재단법인서울대학교산학협력재단 아밀로이드 형성 펩타이드 또는 단백질의 가용성 회합체에선택적으로 작용하는 절단제
KR20090130022A (ko) 2007-03-07 2009-12-17 메사추세츠 인스티튜트 오브 테크놀로지 나노튜브 및 풀러렌을 포함하는 나노규모의 물품의 관능화
WO2008122030A2 (fr) * 2007-04-02 2008-10-09 University Of South Alabama Lavage au dioxyde de carbone utilisant des matières ioniques
LT2247558T (lt) 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
US8951473B2 (en) 2008-03-04 2015-02-10 Massachusetts Institute Of Technology Devices and methods for determination of species including chemical warfare agents
JP2012501344A (ja) * 2008-08-29 2012-01-19 トレヴェンティス コーポレイション アミロイド症を治療する組成物及び方法
US8735313B2 (en) 2008-12-12 2014-05-27 Massachusetts Institute Of Technology High charge density structures, including carbon-based nanostructures and applications thereof
US8456073B2 (en) 2009-05-29 2013-06-04 Massachusetts Institute Of Technology Field emission devices including nanotubes or other nanoscale articles
EA201290007A1 (ru) 2009-08-10 2013-01-30 Беллус Хелс Инк. Способы, соединения и композиции для доставки 1,3-пропандисульфокислоты
US8187887B2 (en) 2009-10-06 2012-05-29 Massachusetts Institute Of Technology Method and apparatus for determining radiation
KR101173677B1 (ko) * 2009-12-11 2012-08-13 한국과학기술연구원 Ｅｐｐｓ를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
US8772537B2 (en) * 2010-07-28 2014-07-08 Sumitomo Chemical Company, Limited Process for producing aminoalkylthiosulfuric acid compound
US8476510B2 (en) 2010-11-03 2013-07-02 Massachusetts Institute Of Technology Compositions comprising and methods for forming functionalized carbon-based nanostructures
MX380290B (es) 2015-08-10 2025-03-12 Alzheon Inc Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
JP6675167B2 (ja) 2015-08-28 2020-04-01 シスメックス株式会社 ペプチドの遊離方法及び回収方法、並びにペプチド遊離剤及び試薬キット
US9556301B1 (en) 2015-12-02 2017-01-31 King Fahd Universoty of Petroleum and Minerals Cyclopolymer containing residues of methionine and synthesis and uses thereof
US10632084B2 (en) 2016-03-04 2020-04-28 Niigata University Aquaporin 4 function promotor and pharmaceutical composition for neurological disorders
RU2657844C1 (ru) * 2017-01-09 2018-06-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения экспериментальной амилоидной кардиопатии у крыс
WO2019090323A1 (fr) 2017-11-06 2019-05-09 Massachusetts Institute Of Technology Graphène à haute densité de fonctionnalisation
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN112912732A (zh) * 2018-08-03 2021-06-04 香港大学 用于淀粉样蛋白原纤维、淀粉样蛋白斑块、rna和核仁的检测和成像的组合物和方法
JP7629182B2 (ja) * 2020-10-02 2025-02-13 Ｏ－Ｆｏｒｃｅ合同会社 アミロイドβの凝集抑制剤、アミロイドβ凝集疾患用医薬組成物、およびその用途
EP3992182A1 (fr) 2020-10-28 2022-05-04 Cisbio Bioassays Complexes d'europium(iii) en tant que capteurs de ph
EP4277884A4 (fr) * 2021-01-11 2024-12-11 Helios Huaming Biopharma Co., Ltd. Composés de salicylamide substitués et leur utilisation
CN113433325A (zh) * 2021-06-07 2021-09-24 西安市第一医院 血清vitronectin在AL型淀粉样变的诊断及疾病分期中的应用
EP4514335A1 (fr) 2022-04-28 2025-03-05 Alzheon, Inc. Tramiprosate pour le traitement de maladies liées à apoe4
CN117384247A (zh) * 2022-11-29 2024-01-12 云南瑞昊生命科技有限公司 一种合成多肽hibp-1及其合成方法和应用
EP4626416A1 (fr) 2022-12-02 2025-10-08 Alzheon, Inc. Méthodes de traitement de troubles neurodégénératifs avec du tramiprosate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085134A (en) * 1974-02-15 1978-04-18 Petrolite Corporation Amino-phosphonic-sulfonic acids
WO1996028187A1 (fr) * 1995-03-15 1996-09-19 Queen's University At Kingston Procedes de traitement de l'amylose
WO1997014306A1 (fr) * 1995-10-17 1997-04-24 Dovetail Technologies, Inc. Stimulants a faible poids moleculaire des cellules de la moelle osseuse et du systeme immunitaire
WO2000064420A2 (fr) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions et procedes pour traiter l'amylose
WO2000071101A2 (fr) * 1999-05-24 2000-11-30 Queen's University At Kingston Procedes et composes permettant d'inhiber les depots amyloides
WO2001003680A2 (fr) * 1999-07-09 2001-01-18 Isis Innovation Limited Composes destines a l'inhibition de maladies et a la preparation de cellules a transplanter

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2376911A (en) * 1941-12-24 1945-05-29 Swiss Company Of Soc Of Chemic Derivatives of sulphonated amines and process of preparing same
DE927992C (de) * 1952-07-27 1955-05-23 Hoechst Ag Verfahren zur Herstellung von Salzen des 1, 2-Dimethyl-3-phenyl-4-amino-5-pyrazolons
US3453309A (en) * 1966-10-14 1969-07-01 Parke Davis & Co Phenylalkylaminoethyl thiosulfates
DE2140278A1 (en) * 1970-01-19 1972-03-09 Crompton and Knowles Corp., Worcester, Mass. (V.St.A.) Water-soluble dyes and dye intermediates
JPS60184564A (ja) * 1984-03-05 1985-09-20 Mitsui Toatsu Chem Inc 液晶に使用するジスアゾ系二色性染料、該染料を含む液晶組成物及び表示装置
DD287256A5 (de) * 1989-08-21 1991-02-21 Akademie Der Wissenschaften Der Ddr,De Verfahren zur herstellung von chiralen wasserloeslichen ammoniumalkansulfonsaeuren sowie deren salzen und sulfobetainen
JP3070687B2 (ja) * 1990-07-19 2000-07-31 日本臓器製薬株式会社 心疾患治療剤
JP3068841B2 (ja) * 1990-08-23 2000-07-24 日本臓器製薬株式会社 アミノアルカンスルホン酸誘導体を有効成分として含有する心疾患治療剤
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
JPH0995444A (ja) * 1995-10-02 1997-04-08 Teijin Ltd アミロイド蛋白凝集阻害剤
WO1998052563A1 (fr) * 1997-05-21 1998-11-26 Shionogi & Co., Ltd. REMEDES CONTRE LA DEMENCE DU TYPE ALZHEIMER CONTENANT DES DERIVES DE η-SULTAME
MXPA01008606A (es) * 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
JP4440446B2 (ja) * 1999-10-05 2010-03-24 花王株式会社 皮膚外用剤
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
NZ540564A (en) * 1999-11-29 2007-04-27 Neurochem Int Ltd Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
WO2001085093A2 (fr) * 1999-12-23 2001-11-15 Neurochem, Inc. Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
WO2004058239A1 (fr) * 2002-12-24 2004-07-15 Neurochem (International) Limited Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide
EP1658264A2 (fr) * 2003-06-23 2006-05-24 Neurochem (International) Limited Procedes et compositions de traitement de maladies associees aux amyloides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085134A (en) * 1974-02-15 1978-04-18 Petrolite Corporation Amino-phosphonic-sulfonic acids
WO1996028187A1 (fr) * 1995-03-15 1996-09-19 Queen's University At Kingston Procedes de traitement de l'amylose
WO1997014306A1 (fr) * 1995-10-17 1997-04-24 Dovetail Technologies, Inc. Stimulants a faible poids moleculaire des cellules de la moelle osseuse et du systeme immunitaire
WO2000064420A2 (fr) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions et procedes pour traiter l'amylose
WO2000071101A2 (fr) * 1999-05-24 2000-11-30 Queen's University At Kingston Procedes et composes permettant d'inhiber les depots amyloides
WO2001003680A2 (fr) * 1999-07-09 2001-01-18 Isis Innovation Limited Composes destines a l'inhibition de maladies et a la preparation de cellules a transplanter

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
ABDERHALDEN; RIESZ, FERMENTFORSCHUNG, 12, 1930, pages 198 *
ALLEN ET AL., ANAL. CHEM., 37, 1965, pages 156 *
CAMPAGNA F. ET AL., FARMACO, vol. 49, no. 10, 1994, pages 653 - 58 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314317, Database accession no. BRN 4261672 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314318, Database accession no. BRN 7023352 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314319, Database accession no. BRN 8919306 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314320, Database accession no. BRN 6023409 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314321, Database accession no. BRN 2272192 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314322, Database accession no. BRN 3948718 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314323, Database accession no. BRN 1712477 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314324, Database accession no. BRN 2972476 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314325, Database accession no. BRN 2434022 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314326, Database accession no. BRN 5620601 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314327, Database accession no. BRN 2846394 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314328, Database accession no. BRN 3952462, 3935697 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314329, Database accession no. BRN5568774 *
DORN, WALTER, Z. CHEM., 7, 1967, pages 151 *
HELFERICH B. ET AL., JUSTUS LIEBIGS ANN. CHEM., 651, 1962, pages 33 - 42 *
IENAGA, KAZUHARA ET AL., CHEM. PHARM. BULL., vol. 36, no. 1, 1988, pages 70 - 77 *
IENAGA, KAZUHARA ET AL., CHEM. PHARM. BULL., vol. 36, no. 8, 1988, pages 2796 - 2801 *
IIDA ET AL., KOGYO KAGAKU ZASSHI, 72, 1969, pages 887 *
ISKANDER MN ET AL., EUR. J. MED. CHEM. CHIM. THER., vol. 26, no. 2, 1991, pages 129 - 136 *
JUSTUS LIEBIGS ANN. CHEM., 647, 1961, pages 37 - 40 *
KILLDAY K. B. ET AL., J. NAT. PROD., vol. 64, no. 4, 2001, pages 525 - 526 *
See also references of EP1644325A2 *
TOMSON ET AL., J. APPL. CHEM. USSR, ENGL. TRANSL., vol. 57, no. 9, 1984, pages 1885 - 91 *
WOOD. J. M. ET AL., J. CHEM. SOC. PERKIN TRANS 2, 5, 2002, pages 938 - 46 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8580859B2 (en) 2008-08-01 2013-11-12 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
US9695119B2 (en) 2008-08-01 2017-07-04 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same

Also Published As

Publication number Publication date
EA200600078A1 (ru) 2006-08-25
CA2529257C (fr) 2013-04-23
BRPI0411743A (pt) 2006-08-08
KR20060023172A (ko) 2006-03-13
WO2004113277A3 (fr) 2005-10-13
AU2004249529A1 (en) 2004-12-29
EP1658264A2 (fr) 2006-05-24
MXPA05013977A (es) 2006-03-09
CA2529257A1 (fr) 2004-12-29
WO2004113277A8 (fr) 2005-07-14
KR101124935B1 (ko) 2012-04-12
NO20055894L (no) 2006-03-21
CA2529256A1 (fr) 2004-12-29
EP1644325A2 (fr) 2006-04-12
JP5146714B2 (ja) 2013-02-20
NZ544684A (en) 2009-10-30
WO2004113277A2 (fr) 2004-12-29
UA96115C2 (uk) 2011-10-10
JP2007516938A (ja) 2007-06-28
NO335084B1 (no) 2014-09-08
WO2004113275A2 (fr) 2004-12-29
MXPA05014166A (es) 2006-03-13
JP2007516939A (ja) 2007-06-28
EA012429B1 (ru) 2009-10-30
AU2004249527A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
WO2004113277A3 (fr) Procedes et compositions de traitement de maladies associees aux amyloides
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2006085149A3 (fr) Methodes et compositions de traitement de maladies liees a l'amyloide
WO2006086562A3 (fr) Derives de phenylazetidinone
WO2005069865A3 (fr) Derives de pyrrolopyrimidine et analogues et utilisation dans le traitement et la prevention de maladies
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2005046603A3 (fr) Composes pyridiniques
AU2005339139A8 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
PL1638938T3 (pl) Związki, kompozycje i sposoby do leczenia i zapobiegania infekcjom ortopokswirusami i powiązanym chorobom
EP1684758A4 (fr) Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
WO2005000208A3 (fr) Therapie combinee pour le traitement des neoplasmes
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2006059252A3 (fr) Procedes et compositions fluorees pour le traitement de maladies associees aux amyloides
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
WO2007059341A3 (fr) Modulateurs de la proteine kinase a base de pyrazolothiazole
WO2004105696A3 (fr) Therapie combinatoire pour le traitement des neoplasmes
AU2003258176A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2004078142A3 (fr) Compositions et methodes de preventions et de traitement de maladies et d'etats pathologiques associes aux endotoxines
AU2003237088A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2007069073A3 (fr) Formulations pharmaceutiques de composes inhibiteurs d'amyloide
AU2003258177A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024207.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172194

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005/09647

Country of ref document: ZA

Ref document number: 200509647

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004249529

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2529257

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/014166

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2004249529

Country of ref document: AU

Date of ref document: 20040621

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020057024647

Country of ref document: KR

Ref document number: 12005502335

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 2004249529

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006516599

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 544684

Country of ref document: NZ

REEP Request for entry into the european phase

Ref document number: 2004744034

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004744034

Country of ref document: EP

Ref document number: 242/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200600078

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: a200600637

Country of ref document: UA

WWP Wipo information: published in national office

Ref document number: 1020057024647

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004744034

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0411743

Country of ref document: BR